FDA Grants Orphan Drug Designation to GSK's B7-H3-Targeted ADC for Small-Cell Lung Cancer
核心洞察
GSK's risvutatug rezetecan (搜索), a B7-H3 (搜索)-targeted antibody-drug conjugate, received FDA Orphan Drug Designation for small-cell lung cancer (搜索) treatment based on durable responses in phase I trials.
The designation addresses extensive stage SCLC (搜索), an aggressive cancer affecting 70% of SCLC patients with only 3% five-year survival rate and limited treatment options.
This marks the fifth regulatory designation for risvutatug rezetecan (搜索), following similar recognition from the European Medicines Agency (搜索) and previous FDA breakthrough therapy designations.
GSK plc announced that its B7-H3 (搜索)-targeted antibody-drug conjugate risvutatug rezetecan (搜索) (formerly GSK'227 (搜索)) has received Orphan Drug Designation from the US Food and Drug Administration for the treatment of small-cell lung cancer (搜索). The designation was supported by preliminary clinical data showing durable responses in patients with extensive stage SCLC (搜索) who were treated with risvutatug rezetecan in the phase I ARTEMIS-001 clinical trial.
Addressing Critical Unmet Medical Need
Small-cell lung cancer (搜索) constitutes approximately 13% of all lung cancers in the United States, with an estimated 29,500 people expected to be diagnosed with SCLC in 2025. Of particular concern, 70% of SCLC patients present with extensive-stage disease, meaning the cancer has spread throughout one or both lungs and/or to other parts of the body.
Extensive stage SCLC (搜索) represents an aggressive and difficult-to-treat cancer with severely limited treatment options. The five-year survival rate is approximately 3%, and most patients with ES-SCLC experience relapse after initial treatment. The median overall survival with standard-of-care treatments for relapsed ES-SCLC is approximately 8 months, highlighting the urgent need for more effective therapeutic approaches.
Expanding Regulatory Recognition
This FDA designation follows GSK's recent announcement that risvutatug rezetecan (搜索) was granted Orphan Drug Designation from the European Medicines Agency (搜索) for the treatment of pulmonary neuroendocrine carcinoma (搜索), a category of cancer that includes SCLC. The current FDA designation represents the fifth regulatory designation for risvutatug rezetecan, demonstrating the potential of this B7-H3 (搜索)-targeted ADC across multiple regulatory jurisdictions.
Previously, risvutatug rezetecan (搜索) received Priority Medicines (PRIME) Designation by the EMA for relapsed or refractory ES-SCLC and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma (搜索) from the US FDA.
Drug Development and Clinical Progress
Risvutatug rezetecan (搜索) (GSK5764227) is a novel investigational B7-H3 (搜索)-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma (搜索) to progress clinical development and commercialization of the compound.
The company is developing risvutatug rezetecan (搜索) across a range of solid tumors, including lung, prostate, and colorectal cancers. GSK's global phase III trial (NCT07099898) for risvutatug rezetecan in relapsed ES-SCLC began in August 2025, marking a significant advancement in the drug's clinical development program.